CN111658676A - 罗伊氏乳杆菌活菌在制备治疗或减轻非酒精性脂肪肝症状的药物中的应用 - Google Patents
罗伊氏乳杆菌活菌在制备治疗或减轻非酒精性脂肪肝症状的药物中的应用 Download PDFInfo
- Publication number
- CN111658676A CN111658676A CN202010531440.5A CN202010531440A CN111658676A CN 111658676 A CN111658676 A CN 111658676A CN 202010531440 A CN202010531440 A CN 202010531440A CN 111658676 A CN111658676 A CN 111658676A
- Authority
- CN
- China
- Prior art keywords
- liver
- lactobacillus reuteri
- fat
- fatty liver
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 23
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 15
- 208000024891 symptom Diseases 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 3
- 230000003908 liver function Effects 0.000 claims abstract description 10
- 206010061218 Inflammation Diseases 0.000 claims abstract description 8
- 230000004054 inflammatory process Effects 0.000 claims abstract description 8
- 230000006378 damage Effects 0.000 claims abstract description 6
- 210000004185 liver Anatomy 0.000 claims description 24
- 208000004930 Fatty Liver Diseases 0.000 claims description 18
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 18
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 17
- 208000010706 fatty liver disease Diseases 0.000 claims description 17
- 230000001737 promoting effect Effects 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 9
- 101150044508 key gene Proteins 0.000 claims description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 7
- 108010082126 Alanine transaminase Proteins 0.000 claims description 7
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 5
- 102000003814 Interleukin-10 Human genes 0.000 claims description 5
- 108090000174 Interleukin-10 Proteins 0.000 claims description 5
- 102000004889 Interleukin-6 Human genes 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- 102000023984 PPAR alpha Human genes 0.000 claims description 5
- 108010028924 PPAR alpha Proteins 0.000 claims description 5
- 108010016731 PPAR gamma Proteins 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000000770 proinflammatory effect Effects 0.000 claims description 3
- 206010019670 Hepatic function abnormal Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 8
- 235000009200 high fat diet Nutrition 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000037356 lipid metabolism Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- -1 SRERP-1c Proteins 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010531440.5A CN111658676B (zh) | 2020-06-11 | 2020-06-11 | 罗伊氏乳杆菌活菌在制备治疗或减轻非酒精性脂肪肝症状的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010531440.5A CN111658676B (zh) | 2020-06-11 | 2020-06-11 | 罗伊氏乳杆菌活菌在制备治疗或减轻非酒精性脂肪肝症状的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111658676A true CN111658676A (zh) | 2020-09-15 |
CN111658676B CN111658676B (zh) | 2021-12-31 |
Family
ID=72386849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010531440.5A Active CN111658676B (zh) | 2020-06-11 | 2020-06-11 | 罗伊氏乳杆菌活菌在制备治疗或减轻非酒精性脂肪肝症状的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111658676B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113403231A (zh) * | 2021-07-08 | 2021-09-17 | 江南大学 | 一株可干预代谢综合征的罗伊氏乳杆菌ccfm1178及应用 |
CN114010665A (zh) * | 2021-11-30 | 2022-02-08 | 西南医科大学附属医院 | 罗伊氏乳杆菌在制备预防和/或治疗酒精性肝病的药物中的应用 |
CN114558039A (zh) * | 2022-03-14 | 2022-05-31 | 江苏省肿瘤医院 | 罗伊氏乳杆菌及其代谢产物在制备治疗肝癌药物中的应用 |
CN116509906A (zh) * | 2023-03-23 | 2023-08-01 | 浙江大学 | 罗伊氏乳杆菌zj617在改善非酒精性脂肪肝和脂肪堆积中的应用 |
KR102578389B1 (ko) * | 2022-11-21 | 2023-09-18 | 마이크로바이오헬스케어 주식회사 | 지방간 개선 효능을 갖는 신규 락토바실러스 루테리 균주 및 이의 용도 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103154235A (zh) * | 2010-02-02 | 2013-06-12 | 生命大地女神有限公司 | 乳杆菌属菌株的免疫调节性质的改善 |
US20140363410A1 (en) * | 2011-12-30 | 2014-12-11 | Biogaia Ab | Lactobacillus Reuteri DSM 17938 for the Development of Cognitive Function |
CN104622886A (zh) * | 2015-03-05 | 2015-05-20 | 中国人民解放军第二军医大学 | 烟酰胺核糖在制备治疗非酒精性脂肪性肝炎的药物中的应用 |
CN104771416A (zh) * | 2014-01-10 | 2015-07-15 | 景岳生物科技股份有限公司 | 用于控制体重的罗伊氏乳杆菌gmnl-263组合物及其用途 |
TW201534312A (zh) * | 2014-03-07 | 2015-09-16 | Genmont Biotech Inc | 用於治療第二型糖尿病的羅伊氏乳桿菌gmnl-89組合物及其用途 |
HK1203315A1 (zh) * | 2011-12-30 | 2015-12-11 | Biogaia Ab | 用於腸神經系統發育的羅伊氏乳桿菌 |
-
2020
- 2020-06-11 CN CN202010531440.5A patent/CN111658676B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103154235A (zh) * | 2010-02-02 | 2013-06-12 | 生命大地女神有限公司 | 乳杆菌属菌株的免疫调节性质的改善 |
US20140363410A1 (en) * | 2011-12-30 | 2014-12-11 | Biogaia Ab | Lactobacillus Reuteri DSM 17938 for the Development of Cognitive Function |
HK1203315A1 (zh) * | 2011-12-30 | 2015-12-11 | Biogaia Ab | 用於腸神經系統發育的羅伊氏乳桿菌 |
CN104771416A (zh) * | 2014-01-10 | 2015-07-15 | 景岳生物科技股份有限公司 | 用于控制体重的罗伊氏乳杆菌gmnl-263组合物及其用途 |
TW201534312A (zh) * | 2014-03-07 | 2015-09-16 | Genmont Biotech Inc | 用於治療第二型糖尿病的羅伊氏乳桿菌gmnl-89組合物及其用途 |
CN104622886A (zh) * | 2015-03-05 | 2015-05-20 | 中国人民解放军第二军医大学 | 烟酰胺核糖在制备治疗非酒精性脂肪性肝炎的药物中的应用 |
Non-Patent Citations (3)
Title |
---|
唐佳 等: "罗伊氏乳杆菌对坏死性小肠结肠炎氧化应激的保护机制", 《J SOUTH MED UNIV》 * |
成艳波 等: "罗伊氏乳杆菌对组胺引起黄颡鱼肝肠损伤修复效果评价", 《水生生物学报》 * |
焦婷 等: "罗伊氏乳杆菌CCFM8631缓解小鼠非酒精性脂肪性肝病与其对肠道菌群及短链脂肪酸的调节显著相关", 《食品与发酵工业》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113403231A (zh) * | 2021-07-08 | 2021-09-17 | 江南大学 | 一株可干预代谢综合征的罗伊氏乳杆菌ccfm1178及应用 |
CN114010665A (zh) * | 2021-11-30 | 2022-02-08 | 西南医科大学附属医院 | 罗伊氏乳杆菌在制备预防和/或治疗酒精性肝病的药物中的应用 |
CN114558039A (zh) * | 2022-03-14 | 2022-05-31 | 江苏省肿瘤医院 | 罗伊氏乳杆菌及其代谢产物在制备治疗肝癌药物中的应用 |
KR102578389B1 (ko) * | 2022-11-21 | 2023-09-18 | 마이크로바이오헬스케어 주식회사 | 지방간 개선 효능을 갖는 신규 락토바실러스 루테리 균주 및 이의 용도 |
CN116509906A (zh) * | 2023-03-23 | 2023-08-01 | 浙江大学 | 罗伊氏乳杆菌zj617在改善非酒精性脂肪肝和脂肪堆积中的应用 |
CN116509906B (zh) * | 2023-03-23 | 2024-04-02 | 浙江大学 | 罗伊氏乳杆菌zj617在改善非酒精性脂肪肝和脂肪堆积中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111658676B (zh) | 2021-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111658676B (zh) | 罗伊氏乳杆菌活菌在制备治疗或减轻非酒精性脂肪肝症状的药物中的应用 | |
JP6608047B2 (ja) | 多様な機能性を有する新規乳酸菌およびその用途 | |
Wang et al. | Preventive effects of total flavonoids of Litsea coreana leve on hepatic steatosis in rats fed with high fat diet | |
WO2023040426A1 (zh) | 缓解代谢综合征的益生菌及其代谢产物配方及其应用 | |
Qian et al. | Effects of lactobacillus casei YBJ02 on lipid metabolism in hyperlipidemic mice | |
JPWO2009066681A1 (ja) | 乳酸菌含有製剤 | |
CN109593678B (zh) | 长双歧杆菌yh295及其在制备降低腹型肥胖风险产品中的应用 | |
Choi et al. | Weissella cibaria MG5285 and Lactobacillus reuteri MG5149 attenuated fat accumulation in adipose and hepatic steatosis in high-fat diet-induced C57BL/6J obese mice | |
TWI627959B (zh) | 羅伊氏乳桿菌GMNL-263 用於製備提升高油脂飲食者肝臟低密度脂蛋白受體與膽固醇7α-羥化酶基因表現之組合物之用途 | |
JP7490801B2 (ja) | 肝機能改善または脂肪蓄積抑制の微生物、及びその用途 | |
CN115011532B (zh) | 一种副干酪乳杆菌jy062制剂及其制备方法和应用 | |
CN113786419A (zh) | 植物乳杆菌lpjz-658在制备用于治疗非酒精性脂肪性肝病中的应用 | |
WO2020006663A1 (zh) | 用于改善代谢症候群的新颖副干酪乳杆菌 gks6、其培养基、培养方法、用途、医药组合物及可食用组合物 | |
TW202118863A (zh) | 保加利亞乳桿菌tci904、其組合物及其用於減少體重的用途 | |
Koontanatechanon et al. | The effects of increasing dietary fat on serum lipid profile and modification of gut microbiome in C57BL/6N mice | |
Lan et al. | Effects of Portulaca oleracea on insulin resistance in rats with type 2 diabetes mellitus | |
CN108048353B (zh) | 一株高表达亚油酸异构酶lai的罗伊乳杆菌hi120及其应用 | |
JP5665196B2 (ja) | 微生物を利用した肥満及び肥満によって引き起こされた代謝性疾患の予防と治療 | |
CN113797232A (zh) | 具有缓解胰岛素抵抗功能的组合物及其应用 | |
KR102401535B1 (ko) | 간 손상 예방, 개선, 또는 치료용 조성물 | |
CN103550790B (zh) | 骨膜蛋白抗体及其在药物制备中的应用 | |
CN109479961A (zh) | 副干酪乳杆菌n1115预防结肠炎的应用及相应的婴幼儿奶粉、应用 | |
CN109045070A (zh) | 一种防治非酒精性脂肪肝病的组合物 | |
CN116376740A (zh) | 一株具有降血糖功效的长双歧杆菌及其应用 | |
CA3148434A1 (en) | Composition and method for preventing, alleviating, or treating liver injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240430 Address after: Room 409-57, Building 20, No. 397 Cangxing Street, Cangqian Street, Yuhang District, Hangzhou City, Zhejiang Province, 310000 Patentee after: Weikang (Hangzhou) Life and Health Technology Co.,Ltd. Country or region after: China Address before: 313008 12a, No. 1088, Dagang Road, Zhili Town, Wuxing District, Huzhou City, Zhejiang Province Patentee before: HUZHOU KINGNOWCARE HEALTH TECHNOLOGY CO.,LTD. Country or region before: China |